TABLE 3.

Treatment-Emergent AEs

	CyclASol 0.1%, n (%)	Vehicle, n (%)
Ocular and nonocular AEs
No. of TEAEs	72	71
No. of subjects with at least one TEAE	49 (30.2)	45 (27.1)
No. of treatment-emergent serious AEs	0	3 (1.8)
No. of subjects discontinued treatment due to an AE	3 (1.9)	0
Ocular AEs*
No. of TEAEs	31	23
No. of subjects with at least 1 TEAE	20 (12.3)	14 (8.4)
Ocular AEs* that occurred in more than 2% of patients
Visual acuity reduced	5 (3.1)	3 (1.8)
Instillation site pain	4 (2.5)	2 (1.2)
Vision blurred	2 (1.2)	4 (2.4)

*Assessment relates to both eyes.